ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury
<p>Abstract</p> <p>Background</p> <p>In contrast with various pre-clinical studies, recent clinical trials suggest that high dose erythropoietin (EPO) treatment following kidney transplantation does not improve short-term outcome and that it even increases the risk of t...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2013-01-01
|
| Series: | Journal of Translational Medicine |
| Subjects: |